Moleculin Biotech, Inc.(MBRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Moleculin Biotech, Inc. (MBRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. MBRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of MBRX by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. MBRX trades on the Nasdaq exchange and files with the SEC under CIK 1659617. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Moleculin Biotech, Inc. directly from SEC EDGAR.

Revenue

$0.00

Net Income

$-7.6M

Institutions holding MBRX

Institutional investors reporting a position in Moleculin Biotech, Inc. on SEC Form 13F.
InstitutionSharesValueReported
GEODE CAPITAL MANAGEMENT47,252$131.8K2026-06-30
VANGUARD CAPITAL MANAGEMENT42,215$117.8K2026-06-30
VANGUARD FIDUCIARY29,883$83.4K2026-06-30
XTX Topco Ltd22,942$64.0K2026-06-30
MORGAN STANLEY20,036$55.9K2026-06-30
Rockefeller Capital Management L.P.15,000$41.9K2026-06-30
Tower Research Capital (TRC)3,514$9.8K2026-06-30
CITIGROUP2,674$7.5K2026-06-30
BARCLAYS PLC621$1.7K2026-06-30
BlackRock491$1.4K2026-06-30
MBRX

Moleculin Biotech, Inc.

MBRX
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$0

Net Income

Q2 2026
EDGAR

$-7.63M

EPS (Diluted)

Q2 2026
EDGAR

$-1.40

Top Institutional Holders

as of Q2 2026
$518.5K total

Financial Trends

Revenue & Net Income

Loading ratio trend…